Skip to main content
Premium Trial:

Request an Annual Quote

Fulgent Genetics, StemCyte Partner on Genetic Testing

NEW YORK (GenomeWeb) – StemCyte will offer two genetic testing services from Fulgent Genetics as part of a partnership announced today.

Under the terms of the deal, StemCyte, a regenerative therapeutics company, will offer Beacon Expanded Carrier Screening and Newborn Genetic Analysis. Beacon Expanded Carrier Screening is used to identify potential reproductive risks for current or future pregnancies, while Newborn Genetic Analysis is for identifying genetic risks in parents but is performed for newborns. It analyzes 255 genes and assesses more than 200 disorders and identifies DNA changes that may cause severe or life-altering symptoms in infants.

Financial and other terms of the deal were not disclosed.

Based in Temple City, California, Fulgent operates a CLIA-certified and CAP-accredited molecular diagnostics lab in Los Angeles. Among the services it provides are full-gene sequencing with deletion/duplication analysis in single-gene tests; testing on pre-established, multigene, disease-specific panels; and testing on customized panels tailored to meet specific clinical needs.

The Scan

Steps for Quick Review

The US Food and Drug Administration is preparing for the quick review of drugs and vaccines for the Omicron variant, according to the Wall Street Journal.

Moving Away From Using Term 'Race'

A new analysis finds that geneticists are using the term "race" in their papers less than in years past, as Science reports.

Point of the Program

The Guardian writes that some scientists have called the design of a UK newborn sequencing program into question.

Science Papers Present Multi-Omic Analysis of Lung Cells, Regulation of Cardiomyocyte Proliferation

In Science this week: a multi-omic analysis of lung cells focuses on RIT1-regulated pathways, and more.